We're Here for You!
The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure.
What’s new in myeloma research? IMF Chairman Dr. Brian G.M. Durie discusses some important new findings from the 2021 American Society of Clinical Oncology (ASCO) annual meeting that took place virtually from June 4-8 this year, and from the subsequent European Hematology Association’s (EHA) annual meeting.
Despite receiving vaccinations, immunocompromised individuals can develop very low levels of antibodies. France and Israel have approved a booster vaccination for the vulnerable. IMF Chairman Dr. Brian G.M. Durie says it’s time for the U.S. to do the same.
Patients, caregivers, and doctors around the world can view the IMF's popular webinar IMWG Conference Series from ASCO 2021. Dr. Brian G.M. Durie, Dr. Thomas Martin, Dr. Maria V. Mateos, and Dr. Nikhil Munshi distill, debate, and discuss the latest news and trends in the treatment of multiple myeloma from the 2021 Annual ASCO Meeting.
According to a press release from Janssen Pharmaceutical Companies of Johnson & Johnson, the U.S. Food and Drug Administration has approved "DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients with multiple myeloma who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor." Click the image to read the full press release.
Need to stay informed about the news that impacts myeloma patients, but don’t have time to read everything out there? Then be sure to follow Dr. Brian Durie’s Week in Review blog. The leading myeloma expert and IMF Chairman of the Board drills down on a wide range of topics – from the latest myeloma research results to the environmental issues that offer insight into prevention. He sifts through the data to deliver the bottom line.
Last year marks the International Myeloma Foundation's (IMF) 30th anniversary, celebrating 30 years of scientific achievement with myeloma patient care at the heart of it all. What started in a garage with a borrowed typewriter is now the largest organization focused specifically on multiple myeloma. The IMF continues to push the needle forward toward a cure for myeloma with cure-focused trials and over 40 active research projects around the world. As IMF President and Founder Susie Durie says, "We are this close to the cure. I can see it on the horizon."
The support of loved ones allows us to continue to fund efforts to search for a cure. Check out how Fundraisers are helping in the fight against myeloma.
